Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that interim...

Preclinical data demonstrate presence of CD161 expressing T cells in anti-PD1 non-responder tumors and enhanced T cell mediated cytotoxicity with combination treatment of IMT-009 and anti-PD1,...

Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR-driven cancers, today announced poster...

Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage immunology company, today announced it will be providing updates on its RNA immunotherapies at multiple presentations at the American...

-Sapience to present data across its pipeline, including non-clinical immunotherapy results on ST316 and ST101 and preclinical results on its novel AP-1 complex antagonist TARRYTOWN, N.Y., March...